|Articles|April 13, 2022
Improving Titer, Quality and Efficiency of AAV Manufacturing and Production by Optimizing Osmolality
Author(s)Advanced Instruments
Modulating osmolality in the early stages of AAV1 upstream manufacturing, can result in improved outcomes such as overall yield, quality, reduced manufacturing costs and improved efficiencies.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
A-TEEM: A Novel, Powerful Tool for Evaluating and Monitoring Cell Culture Media
2
Challenges, Innovations, and Future Outlook of Biologics Formulations
3
Behind the Headlines Episode 27: Unpacking Mega Deals and R&D Directions
4
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
5
